Halozyme Therapeutics (HALO) Other Non Operating Income (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Other Non Operating Income data on file, last reported at $1.3 million in Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $1.3 million, down 80.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.0 million (down 37.55% YoY), and the FY2025 annual result was $21.5 million, down 9.6% from the prior year.
• Other Non Operating Income slipped to $1.3 million in Q1 2026 per HALO's latest filing, from $2.4 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $7.3 million in Q4 2024 and troughed at -$945000.0 in Q2 2022.
• A 5-year average of $3.8 million and a median of $4.8 million in 2023 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Other Non Operating Income tumbled 527.6% in 2022, then surged 646.65% in 2023.
• A 5-year view of Other Non Operating Income shows it stood at $852000.0 in 2022, then soared by 529.11% to $5.4 million in 2023, then soared by 35.32% to $7.3 million in 2024, then tumbled by 66.5% to $2.4 million in 2025, then slumped by 45.76% to $1.3 million in 2026.
• Business Quant data shows HALO's Other Non Operating Income at $1.3 million in Q1 2026, $2.4 million in Q4 2025, and $5.3 million in Q3 2025.